PATENT CLAIM ANALYSIS

Application Number: 16207854
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["544", "006000"]

Abstract:
The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

Claim (Index 22):
The compound according to  claim 1 ,\n wherein R 1  means \u2014H or \u2014CH 3 ; R 2  means \u2014C 1 -C 6 -alkyl, linear or branched, saturated, unsubstituted; cyclopropyl connected through \u2014CH 2 \u2014; or tetrahydropyranyl connected through \u2014CH 2 \u2014; R 3  means -phenyl, benzyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014CN, \u2014CH 3 , \u2014CH 2 CH 3 , \u2014CH 2 F, \u2014CHF 2 , \u2014CF 3 , \u2014OCF 3 , \u2014OH, \u2014OCH 3 , \u2014C(\u2550O)NH 2 , C(\u2550O)NHCH 3 , \u2014C(\u2550O)N(CH 3 ) 2 , \u2014NH 2 , \u2014NHCH 3 , \u2014N(CH 3 ) 2 , \u2014NHC(\u2550O)CH 3 , \u2014CH 2 OH, SOCH 3  and SO 2 CH 3 ; or R 4  means \u2014H; \u2014C 1 -C 6 -alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014OH, \u2014O\u2014C 1 -C 4 -alkyl, \u2014C(\u2550O)NH\u2014C 1 -C 6 -alkyl, \u2014C(\u2550O)N(C 1 -C 6 -alkyl) 2  or \u2014C(\u2550O)NRR\u2032 wherein R and R\u2032 together with the nitrogen atom to which they are attached form a ring and mean \u2014(CH 2 ) 3-5 \u2014; 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014OH, and \u2014O\u2014C 1 -C 4 -alkyl, wherein said 3-6-membered cycloalkyl is connected through \u2014C 1 -C 6 -alkylene; 3-6-membered heterocycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014OH, and \u2014O\u2014C 1 -C 4 -alkyl, wherein said 3-6-membered heterocycloalkyl is connected through \u2014C 1 -C 6 -alkylene; -phenyl, unsubstituted or monosubstituted with \u2014OCH 3 ; wherein said -phenyl is connected through \u2014C 1 -C 6 -alkylene-; or -pyridyl, unsubstituted, mono- or polysubstituted; wherein said -pyridyl is connected through \u2014C 1 -C 6 -alkylene-; R 5  means -phenyl, -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of\n \u2014F; \u2014Cl; \u2014Br; \u2014I; \n \u2014CN; \u2014C 1 -C 4 -alkyl; \u2014C 1 -C 4 -alkyl-OH; \u2014CF 3 ; \u2014C 1 -C 4 -alkyl-CF 3 ; \u2014C 1 -C 4 -alkyl-C(\u2550O)NH 2 ; \u2014C 1 -C 4 -alkyl-C(\u2550O)NHC 1 -C 6 -alkyl; \u2014C 1 -C 4 -alkyl-C(\u2550O)N(C 1 -C 6 -alkyl) 2 ; \u2014C 1 -C 4 -alkyl-S(\u2550O) 2 \u2014C 1 -C 4 -alkyl; \n \u2014C(\u2550O)\u2014C 1 -C 4 -alkyl; \u2014C(\u2550O)OH; \u2014C(\u2550O)O\u2014C 1 -C 4 -alkyl; \u2014C(\u2550O)NH 2 ; \u2014C(\u2550O)NHC 1 -C 4 -alkyl; \u2014C(\u2550O)N(C 1 -C 4 -alkyl) 2 ; \u2014C(\u2550O)NH(C 1 -C 4 -alkyl-OH); \u2014C(\u2550O)N(C 1 -C 4 -alkyl)(C 1 -C 4 -alkyl-OH); \u2014C(\u2550O)NH\u2014(CH 2 CH 2 O) 1-30 \u2014CH 3 ; \n \u2014NH 2 ; \u2014NHC 1 -C 4 -alkyl; \u2014N(C 1 -C 4 -alkyl) 2 ; \u2014NHC 1 -C 4 -alkyl-OH; \u2014NCH 3 C 1 -C 4 -alkyl-OH; \u2014NH\u2014C 1 -C 4 -alkyl-C(\u2550O)NH 2 ; \u2014NCH 3 \u2014C 1 -C 4 -alkyl-C(\u2550O)NH 2 ; \u2014NHC(\u2550O)\u2014C 1 -C 4 -alkyl; \u2014NCH 3 C(\u2550O)\u2014C 1 -C 4 -alkyl; \n \u2014OH; \u2014O\u2014C 1 -C 4 -alkyl; \u2014OCF 3 ; \u2014O\u2014C 1 -C 4 -alkyl-CO 2 H; \u2014O\u2014C 1 -C 4 -alkyl-C(\u2550O)O\u2014C 1 -C 4 -alkyl; \u2014O\u2014C 1 -C 4 -alkyl-CONH 2 ; \n \u2014S\u2014C 1 -C 4 -alkyl; \u2014S(\u2550O)C 1 -C 4 -alkyl; \u2014S(\u2550O) 2 C 1 -C 4 -alkyl; and \u2014S(\u2550O) 2 N(C 1 -C 4 -alkyl) 2 ; \n 3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl is optionally connected through \u2014CH 2 \u2014, \u2014O\u2014, \u2014NH\u2014, \u2014NCH 3 \u2014, \u2014NH\u2014(CH 2 ) 1-3 \u2014, \u2014NCH 3 (CH 2 ) 1-3 \u2014, \u2014(C\u2550O)\u2014, \u2014NHC(\u2550O)\u2014, \u2014NCH 3 C(\u2550O)\u2014, \u2014C(\u2550O)NH\u2014(CH 2 ) 1-3 \u2014, \u2014C(\u2550O)NCH 3 \u2014(CH 2 ) 1-3 \u2014; \n 3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl is optionally connected through \u2014CH 2 \u2014, \u2014O\u2014, \u2014NH\u2014, \u2014NCH 3 \u2014, \u2014NH\u2014(CH 2 ) 1-3 \u2014, \u2014NCH 3 (CH 2 ) 1-3 \u2014, \u2014(C\u2550O)\u2014, \u2014NHC(\u2550O)\u2014, \u2014NCH 3 C(\u2550O)\u2014, \u2014C(\u2550O)NH\u2014(CH 2 ) 1-3 \u2014, \u2014C(\u2550O)NCH 3 \u2014(CH 2 ) 1-3 \u2014; \n 6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is optionally connected through \u2014CH 2 \u2014, \u2014O\u2014, \u2014NH\u2014, \u2014NCH 3 \u2014, \u2014NH\u2014(CH 2 ) 1-3 \u2014, \u2014NCH 3 (CH 2 ) 1-3 \u2014, \u2014(C\u2550O)\u2014, \u2014NHC(\u2550O)\u2014, \u2014NCH 3 C(\u2550O)\u2014, \u2014C(\u2550O)NH\u2014(CH 2 ) 1-3 \u2014, \u2014C(\u2550O)NCH 3 \u2014(CH 2 ) 1-3 \u2014; or \n 5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is optionally connected through \u2014CH 2 \u2014, \u2014O\u2014, \u2014NH\u2014, \u2014NCH 3 \u2014, \u2014NH\u2014(CH 2 ) 1-3 \u2014, \u2014NCH 3 (CH 2 ) 1-3 \u2014, \u2014(C\u2550O)\u2014, \u2014NHC(\u2550O)\u2014, \u2014NCH 3 C(\u2550O)\u2014, \u2014C(\u2550O)NH\u2014(CH 2 ) 1-3 \u2014, \u2014C(\u2550O)NCH 3 \u2014(CH 2 ) 1-3 \u2014; \n and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , and R 20  mean \u2014H.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.17857
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15125615', '12604691', '12699451', '15326138', '12700857']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.864382115082554
- 35 USC 102 Novelty (BERT): 0.5510695365835323
- Combined Prediction Score: 0.8330508572326519
- Mean Citation Score: 423.427142
- Max Citation Score: 437.00952
- Similarity Product: 356.3973702674961

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test